Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek December 27, 2004 Kerry Capell	The End Of Obesity As We Know It Sanofi-Aventis' Acomplia takes aim at two of the great maladies of the century. But approval isn't a slam dunk.
The Motley Fool July 16, 2010 Brian Orelli	Why VIVUS Is 57% Thinner In a move that slashed the pharmaceutical's shares, Food and Drug Administration advisory committee recommended that the agency not approve their obesity drug Qnexa.
The Motley Fool March 16, 2004 David Nierengarten	Sanofi Slimming Pill Sanofi's new drug, Acomplia, shows promise for weight loss and smoking cessation.
The Motley Fool December 11, 2006 Brian Lawler	Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made.
The Motley Fool March 9, 2005 Brian Gorman	Sanofi's Answer to Obesity Sanofi-Aventis will ask for FDA approval of an exciting new drug that may work for a variety of addictions.
The Motley Fool January 26, 2005 Stephen D. Simpson	Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation.
The Motley Fool April 26, 2004 J. Graham	Sanofi Finally Nabs Aventis The French drug companies make a deal to merge.
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
The Motley Fool May 13, 2005 Stephen D. Simpson	Waiting for Sanofi's Next Act Sanofi-Aventis' first-quarter numbers were good. Will they soon be better? Though the stock is not the greatest idea for highly income-oriented investors, the growth-at-a-reasonable-price crowd might want to investigate further.
The Motley Fool June 6, 2008 Brian Lawler	Sorry, Sanofi: More Bad News The pharmaceutical's top drug prospect is linked to more side effects.
The Motley Fool August 31, 2005 Stephen D. Simpson	Sanofi-Aventis: A Mix of News The company gave investors a lot of information for the second quarter, with not all of it positive.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch.
The Motley Fool July 13, 2010 Brian Orelli	A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight.
Pharmaceutical Executive July 3, 2007 Patrick Clinton	From the Editor: Post-regulatory The Editor-in-Chief of this publication speaks out about drug safety, and drug availability, in the post-regulatory world.
BusinessWeek December 27, 2004 Carol Matlack	Growing Pains At Sanofi The pipeline looks good at the world's No. 3 drugmaker -- but investors are waiting for cost cuts.
The Motley Fool February 20, 2007 Brian Lawler	Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
The Motley Fool April 16, 2010 Brian Orelli	It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet.
The Motley Fool December 13, 2010 Brian Orelli	Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price.
The Motley Fool December 22, 2010 Brian Orelli	Arena Charges On It seems Fool readers were a little more optimistic about the timing of Arena Pharmaceuticals' resubmission of its obesity drug to the Food and Drug Administration than the company is.
The Motley Fool July 16, 2010 Tom Hughes	Lessons Learned About the Outlook for New Obesity Drug Approval The recent FDA advisory committee meeting on Vivus' weight loss pill proved to us, once again, how incredibly difficult it is to successfully develop and register new drugs for obesity.
The Motley Fool December 14, 2005 Stephen D. Simpson	Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster.
The Motley Fool March 30, 2009 Brian Orelli	Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration.
The Motley Fool September 11, 2008 Brian Lawler	Will a Change Cure Sanofi? The drugmaker charts a different course for its future.
The Motley Fool February 10, 2009 Robert Steyer	Rx for a Drug Deal? Will circumstance and psychology prod Sanofi-Aventis into a big acquisition?
The Motley Fool October 19, 2010 Brian Orelli	Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
The Motley Fool November 7, 2008 Brian Orelli	Thinning Out the Pipeline The FDA says no to diet drugs from Sanofi-Aventis and Pfizer.
Chemistry World July 2007 Lisa Melton	There's More to Quitting Than Nicotine As England joins the growing list of nations to ban smoking in enclosed public places, this article explores the medicinal arsenal that could help to kick the habit
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
BusinessWeek February 9, 2004 Kerry Cappell	This Bid Looks Like Bad Medicine Sanofi's lowball offer for giant drugmaker Aventis is unwise for both companies
The Motley Fool October 3, 2008 Brian Orelli	Merck Can't Fight the Munchies The pharma gives up on its anti-obesity drug.
BusinessWeek March 29, 2004 Kerry Capell	A Drug Behemoth In The Making? Novartis plus Aventis would create the world's No. 2 drugmaker, unless politics get in the way
BusinessWeek February 27, 2006 Catherine Arnst	Weight Loss: The Spirit Is Willing -- But Pills Work Doctors may decide that weight loss is best accomplished with the new drug Acomplia.
The Motley Fool August 15, 2007 Brian Orelli	Buffett's Drug Deals During the most recent quarter Berkshire Hathaway has increased their holdings in several battered pharmaceutical and medical stocks.
Chemistry World October 5, 2010 Andrew Turley	Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board.
The Motley Fool March 19, 2009 Brian Orelli	One Down, One to Go Sanofi-aventis slides past an FDA panel and hopes for more good news today
The Motley Fool March 4, 2010 Brian Orelli	Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing.
The Motley Fool January 13, 2006 Stephen D. Simpson	Pfizer Pays Sanofi to Go Away Two large pharmaceutical companies settle a dispute over inhaled insulin, and $1.3 billion changes hands. Investors, take note.
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
The Motley Fool July 2, 2009 Robert Steyer	At Last, a Heartening Drug Approval French drug giant sanofi-aventis gets FDA approval for a drug to treat an erratic heartbeat.
The Motley Fool March 14, 2008 Brian Orelli	Weighing In on Obesity Drugs Could investing in drugmakers that produce weight-loss drugs help fatten your wallet?
The Motley Fool February 14, 2008 Brian Lawler	Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops.
The Motley Fool September 14, 2010 Brian Orelli	42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason.
The Motley Fool May 5, 2006 Stephen D. Simpson	Sanofi-Aventis Waits It Out This is the hurry up-and-wait part of the French pharma's story, with product approvals on the way soon, investors hope.
The Motley Fool November 17, 2009 Dave Mock	A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst.
The Motley Fool October 30, 2009 Brian Orelli	Shrugging Off the Side Effects Sanofi-aventis is looking good, but still faces the patent protection loss of Lovenox.
Nurse Practitioner April 2012 Chaney & Sheriff	Evidence-based treatments for smoking cessation Smoking addiction is both physical and mental. The etiology of tobacco dependence is multidimensional and includes physiological, psychological, and social/behavioral factors.
The Motley Fool November 12, 2009 Kris Eddy	Drug Companies Should Think Smaller Sanofi-aventis looks to break R&D into smaller chunks; their collaboration with Regeneron Pharmaceuticals is a good example of the new strategy.
The Motley Fool September 24, 2008 Brian Lawler	Sanofi Gets the Golden Ring Sanofi-Aventis raises its bid and acquires Czech generic drugmaker Zentiva.
AskMen.com July 7, 2014 Patrick Owen	Is It Impossible To Keep The Weight Off? The world is fatter than ever. In 2010 there were 1.5 billion people worldwide who were obese, and the trend is growing.